ATAO: Altair International Corp. Stock

SIC 3841 – Surgical and Medical Instruments and Apparatus

Valuation
Market Cap ($M) 11.19
Enterprise Value ($M) 22.11
Book Value ($M) -1.56
Book Value / Share -0.01
Price / Book -7.18
NCAV ($M) -28.31
NCAV / Share -0.10
Price / NCAV -0.40

Profitability (mra)
Return on Invested Capital (ROIC) -0.09
Return on Assets (ROA) -0.32
Return on Equity (ROE) -1.48

Liquidity (mrq)
Quick Ratio 0.19
Current Ratio 0.19

Balance Sheet (mrq) ($M)
Current Assets 1.00
Assets 27.75
Liabilities 29.31
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 20.75
Operating Income -1.15
Net Income -2.19
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 3.09
Cash from Investing -0.93
Cash from Financing -2.07

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-07-02 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR

(click for more detail)

Similar Companies
AFIB – Acutus Medical, Inc. AHICF – Asahi Intecc Co., Ltd.
ARTHQ – Arch Therapeutics, Inc. AURX – Nuo Therapeutics, Inc.
BIOLQ – BIOLASE, Inc.


Financial data and stock pages provided by
Fintel.io